Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3888MR)

This product GTTS-WQ3888MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3888MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13048MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5662MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ2848MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ13357MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ3287MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ10969MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ16006MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ13870MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW